Skip to main content
Erschienen in: Supportive Care in Cancer 9/2014

01.09.2014 | Original Article

Does perceived control predict Complementary and Alternative Medicine (CAM) use among patients with lung cancer? A cross-sectional survey

verfasst von: Joshua Bauml, Corey J. Langer, Tracey Evans, Sheila N. Garland, Krupali Desai, Jun J. Mao

Erschienen in: Supportive Care in Cancer | Ausgabe 9/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Scant literature exists on the use of complementary and alternative medicine (CAM) among patients with lung cancer. Preliminary data indicates that perceived control is an important factor leading patients to CAM. This study aimed to evaluate the relationship between perceived control and CAM use in patients with lung cancer.

Methods

We performed a cross-sectional survey in patients with lung cancer under active treatment and follow-up at the oncology clinic of an academic medical center. Self-reported CAM use was the primary outcome. Multivariate logistic regression was performed to determine the relationship between perceived control and CAM use, controlling for other factors.

Results

Among 296 participants, 54.4 % were female, 83.5 % were Caucasian, 57.6 % were ≤65 years old, 52.4 % were in stage IV, and 86.4 % had non-small cell lung cancer; 50.9 % of patients had used CAM, most commonly vitamins (31.5 %), herbs (19.3 %), relaxation techniques (16 %), and special diets (15.7 %). In multivariate analysis, CAM use was associated with having greater perceived control over the cause of cancer (adjusted odds ratio (AOR) 2.27, 95 % confidence interval (CI) 1.35–3.80), age ≤ 65 (AOR 1.64, 95 % CI 1.01–2.67), higher education (AOR 2.17, 95 % CI 1.29–3.64), and never having smoked tobacco (AOR 2.39, 95 % CI 1.25–4.54). Nearly 60 % of patients who used CAM were receiving active treatment.

Conclusion

Over half of lung cancer patients have used CAM since diagnosis. Greater perceived control over the cause of cancer was associated with CAM use. Given the high prevalence of CAM, it is essential that oncologists caring for patients with lung cancer discuss its use.
Literatur
1.
Zurück zum Zitat Amichai T, Grossman M, Richard M (2012) Lung cancer patients’ beliefs about complementary and alternative medicine in the promotion of their wellness. Eur J Oncol Nurs Off J Eur Oncol Nurs Soc 16:520–527CrossRef Amichai T, Grossman M, Richard M (2012) Lung cancer patients’ beliefs about complementary and alternative medicine in the promotion of their wellness. Eur J Oncol Nurs Off J Eur Oncol Nurs Soc 16:520–527CrossRef
2.
Zurück zum Zitat Balneaves LG, Kristjanson LJ, Tataryn D (1999) Beyond convention: describing complementary therapy use by women living with breast cancer. Patient Educ Couns 38:143–153PubMedCrossRef Balneaves LG, Kristjanson LJ, Tataryn D (1999) Beyond convention: describing complementary therapy use by women living with breast cancer. Patient Educ Couns 38:143–153PubMedCrossRef
3.
Zurück zum Zitat Barez M, Blasco T, Fernandez-Castro J, Viladrich C (2007) A structural model of the relationships between perceived control and adaptation to illness in women with breast cancer. J Psychosoc Oncol 25:21–43PubMedCrossRef Barez M, Blasco T, Fernandez-Castro J, Viladrich C (2007) A structural model of the relationships between perceived control and adaptation to illness in women with breast cancer. J Psychosoc Oncol 25:21–43PubMedCrossRef
4.
Zurück zum Zitat Boon H, Stewart M, Kennard MA, Gray R, Sawka C, Brown JB, McWilliam C, Gavin A, Baron RA, Aaron D, Haines-Kamka T (2000) Use of complementary/alternative medicine by breast cancer survivors in Ontario: prevalence and perceptions. J Clin Oncol 18:2515–2521PubMed Boon H, Stewart M, Kennard MA, Gray R, Sawka C, Brown JB, McWilliam C, Gavin A, Baron RA, Aaron D, Haines-Kamka T (2000) Use of complementary/alternative medicine by breast cancer survivors in Ontario: prevalence and perceptions. J Clin Oncol 18:2515–2521PubMed
5.
6.
Zurück zum Zitat Costanzo ES, Lutgendorf SK, Roeder SL (2011) Common-sense beliefs about cancer and health practices among women completing treatment for breast cancer. Psychooncology 20:53–61PubMedCentralPubMedCrossRef Costanzo ES, Lutgendorf SK, Roeder SL (2011) Common-sense beliefs about cancer and health practices among women completing treatment for breast cancer. Psychooncology 20:53–61PubMedCentralPubMedCrossRef
7.
Zurück zum Zitat D'Andrea GM (2005) Use of antioxidants during chemotherapy and radiotherapy should be avoided CA. Cancer J Clin 55:319–321CrossRef D'Andrea GM (2005) Use of antioxidants during chemotherapy and radiotherapy should be avoided CA. Cancer J Clin 55:319–321CrossRef
8.
Zurück zum Zitat Degner LF, Sloan JA (1995) Symptom distress in newly diagnosed ambulatory cancer patients and as a predictor of survival in lung cancer. J Pain Symptom Manag 10:423–431CrossRef Degner LF, Sloan JA (1995) Symptom distress in newly diagnosed ambulatory cancer patients and as a predictor of survival in lung cancer. J Pain Symptom Manag 10:423–431CrossRef
9.
Zurück zum Zitat DeSalvo KB, Bloser N, Reynolds K, He J, Muntner P (2006) Mortality prediction with a single general self-rated health question. A meta-analysis. J Gen Intern Med 21:267–275PubMedCentralPubMedCrossRef DeSalvo KB, Bloser N, Reynolds K, He J, Muntner P (2006) Mortality prediction with a single general self-rated health question. A meta-analysis. J Gen Intern Med 21:267–275PubMedCentralPubMedCrossRef
10.
Zurück zum Zitat Eisenberg DM, Kessler RC, Van Rompay MI, Kaptchuk TJ, Wilkey SA, Appel S, Davis RB (2001) Perceptions about complementary therapies relative to conventional therapies among adults who use both: results from a national survey. Ann Intern Med 135:344–351PubMedCrossRef Eisenberg DM, Kessler RC, Van Rompay MI, Kaptchuk TJ, Wilkey SA, Appel S, Davis RB (2001) Perceptions about complementary therapies relative to conventional therapies among adults who use both: results from a national survey. Ann Intern Med 135:344–351PubMedCrossRef
11.
Zurück zum Zitat Faller H, Schilling S, Lang H (1995) Causal attribution and adaptation among lung cancer patients. J Psychosom Res 39:619–627PubMedCrossRef Faller H, Schilling S, Lang H (1995) Causal attribution and adaptation among lung cancer patients. J Psychosom Res 39:619–627PubMedCrossRef
12.
Zurück zum Zitat Frenkel M, Abrams DI, Ladas EJ, Deng G, Hardy M, Capodice JL, Winegardner MF, Gubili JK, Yeung KS, Kussmann H, Block KI (2013) Integrating dietary supplements into cancer care. Integr Cancer Ther 2(5):369–384CrossRef Frenkel M, Abrams DI, Ladas EJ, Deng G, Hardy M, Capodice JL, Winegardner MF, Gubili JK, Yeung KS, Kussmann H, Block KI (2013) Integrating dietary supplements into cancer care. Integr Cancer Ther 2(5):369–384CrossRef
13.
Zurück zum Zitat Gansler T, Kaw C, Crammer C, Smith T (2008) A population-based study of prevalence of complementary methods use by cancer survivors: a report from the American Cancer Society’s studies of cancer survivors. Cancer 113:1048–1057PubMedCrossRef Gansler T, Kaw C, Crammer C, Smith T (2008) A population-based study of prevalence of complementary methods use by cancer survivors: a report from the American Cancer Society’s studies of cancer survivors. Cancer 113:1048–1057PubMedCrossRef
14.
Zurück zum Zitat Ge J, Fishman J, Vapiwala N, Li SQ, Desai K, Xie SX, Mao JJ (2013) Patient-physician communication about complementary and alternative medicine in a radiation oncology setting. Int J Radiat Oncol Biol Phys 85:e1–e6PubMedCentralPubMedCrossRef Ge J, Fishman J, Vapiwala N, Li SQ, Desai K, Xie SX, Mao JJ (2013) Patient-physician communication about complementary and alternative medicine in a radiation oncology setting. Int J Radiat Oncol Biol Phys 85:e1–e6PubMedCentralPubMedCrossRef
15.
Zurück zum Zitat Gerrig RJ, Zimbardo PG (2002) Psychology and life. Allyn and Bacon, Boston Gerrig RJ, Zimbardo PG (2002) Psychology and life. Allyn and Bacon, Boston
16.
Zurück zum Zitat Henderson JW, Donatelle RJ (2003) The relationship between cancer locus of control and complementary and alternative medicine use by women diagnosed with breast cancer. Psychooncology 12:59–67PubMedCrossRef Henderson JW, Donatelle RJ (2003) The relationship between cancer locus of control and complementary and alternative medicine use by women diagnosed with breast cancer. Psychooncology 12:59–67PubMedCrossRef
17.
Zurück zum Zitat Irwin KE, Greer JA, Khatib J, Temel JS, Pirl WF (2013) Early palliative care and metastatic non-small cell lung cancer: potential mechanisms of prolonged survival. Chron Respir Dis 10:35–47PubMedCrossRef Irwin KE, Greer JA, Khatib J, Temel JS, Pirl WF (2013) Early palliative care and metastatic non-small cell lung cancer: potential mechanisms of prolonged survival. Chron Respir Dis 10:35–47PubMedCrossRef
18.
Zurück zum Zitat Kidd L, Hubbard G, O'Carroll R, Kearney N (2009) Perceived control and involvement in self care in patients with colorectal cancer. J Clin Nurs 18:2292–2300PubMedCrossRef Kidd L, Hubbard G, O'Carroll R, Kearney N (2009) Perceived control and involvement in self care in patients with colorectal cancer. J Clin Nurs 18:2292–2300PubMedCrossRef
19.
Zurück zum Zitat Lee RT, Hlubocky FJ, Hu JJ, Stafford RS, Daugherty CK (2008) An international pilot study of oncology physicians’ opinions and practices on Complementary and Alternative Medicine (CAM). Integr Cancer Ther 7:70–75PubMedCrossRef Lee RT, Hlubocky FJ, Hu JJ, Stafford RS, Daugherty CK (2008) An international pilot study of oncology physicians’ opinions and practices on Complementary and Alternative Medicine (CAM). Integr Cancer Ther 7:70–75PubMedCrossRef
20.
21.
Zurück zum Zitat Maggiore RJ, Gross CP, Togawa K, Tew WP, Mohile SG, Owusu C, Klepin HD, Lichtman SM, Gajra A, Ramani R, Katheria V, Klapper SM, Hansen K, Hurria A, on behalf of the C, Aging Research G (2012) Use of complementary medications among older adults with cancer. Cancer 118:4815–4823PubMedCentralPubMedCrossRef Maggiore RJ, Gross CP, Togawa K, Tew WP, Mohile SG, Owusu C, Klepin HD, Lichtman SM, Gajra A, Ramani R, Katheria V, Klapper SM, Hansen K, Hurria A, on behalf of the C, Aging Research G (2012) Use of complementary medications among older adults with cancer. Cancer 118:4815–4823PubMedCentralPubMedCrossRef
22.
Zurück zum Zitat Mao JJ, Cronholm PF, Stein E, Straton JB, Palmer SC, Barg FK (2010) Positive changes, increased spiritual importance, and complementary and alternative medicine (CAM) use among cancer survivors. Integr Cancer Ther 9:339–347PubMedCrossRef Mao JJ, Cronholm PF, Stein E, Straton JB, Palmer SC, Barg FK (2010) Positive changes, increased spiritual importance, and complementary and alternative medicine (CAM) use among cancer survivors. Integr Cancer Ther 9:339–347PubMedCrossRef
23.
Zurück zum Zitat Mao JJ, Farrar JT, Xie SX, Bowman MA, Armstrong K (2007) Use of complementary and alternative medicine and prayer among a national sample of cancer survivors compared to other populations without cancer. Complement Ther Med 15:21–29PubMedCrossRef Mao JJ, Farrar JT, Xie SX, Bowman MA, Armstrong K (2007) Use of complementary and alternative medicine and prayer among a national sample of cancer survivors compared to other populations without cancer. Complement Ther Med 15:21–29PubMedCrossRef
24.
Zurück zum Zitat Mao JJ, Palmer CS, Healy KE, Desai K, Amsterdam J (2011) Complementary and alternative medicine use among cancer survivors: a population-based study. J Cancer Surviv Res Pract 5:8–17CrossRef Mao JJ, Palmer CS, Healy KE, Desai K, Amsterdam J (2011) Complementary and alternative medicine use among cancer survivors: a population-based study. J Cancer Surviv Res Pract 5:8–17CrossRef
25.
Zurück zum Zitat Molassiotis A, Panteli V, Patiraki E, Ozden G, Platin N, Madsen E, Browall M, Fernandez-Ortega P, Pud D, Margulies A (2006) Complementary and alternative medicine use in lung cancer patients in eight European countries. Complement Ther Clin Pract 12:34–39PubMedCrossRef Molassiotis A, Panteli V, Patiraki E, Ozden G, Platin N, Madsen E, Browall M, Fernandez-Ortega P, Pud D, Margulies A (2006) Complementary and alternative medicine use in lung cancer patients in eight European countries. Complement Ther Clin Pract 12:34–39PubMedCrossRef
26.
Zurück zum Zitat Montazeri A, Milroy R, Hole D, McEwen J, Gillis CR (2001) Quality of life in lung cancer patients: as an important prognostic factor. Lung Cancer 31:233–240PubMedCrossRef Montazeri A, Milroy R, Hole D, McEwen J, Gillis CR (2001) Quality of life in lung cancer patients: as an important prognostic factor. Lung Cancer 31:233–240PubMedCrossRef
27.
Zurück zum Zitat O'Connell JP, Kris MG, Gralla RJ, Groshen S, Trust A, Fiore JJ, Kelsen DP, Heelan RT, Golbey RB (1986) Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. J Clin Oncol 4:1604–1614PubMed O'Connell JP, Kris MG, Gralla RJ, Groshen S, Trust A, Fiore JJ, Kelsen DP, Heelan RT, Golbey RB (1986) Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy. J Clin Oncol 4:1604–1614PubMed
28.
Zurück zum Zitat Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL, Valanis B, Williams JH, Barnhart S, Hammar S (1996) Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 334:1150–1155PubMedCrossRef Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL, Valanis B, Williams JH, Barnhart S, Hammar S (1996) Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 334:1150–1155PubMedCrossRef
29.
Zurück zum Zitat Paltiel O, Avitzour M, Peretz T, Cherny N, Kaduri L, Pfeffer RM, Wagner N, Soskolne V (2001) Determinants of the use of complementary therapies by patients with cancer. J Clin Oncol 19:2439–2448PubMed Paltiel O, Avitzour M, Peretz T, Cherny N, Kaduri L, Pfeffer RM, Wagner N, Soskolne V (2001) Determinants of the use of complementary therapies by patients with cancer. J Clin Oncol 19:2439–2448PubMed
30.
Zurück zum Zitat Paull DE, Thomas ML, Meade GE, Updyke GM, Arocho MA, Chin HW, Adebonojo SA, Little AG (2006) Determinants of quality of life in patients following pulmonary resection for lung cancer. Am J Surg 192:565–571PubMedCrossRef Paull DE, Thomas ML, Meade GE, Updyke GM, Arocho MA, Chin HW, Adebonojo SA, Little AG (2006) Determinants of quality of life in patients following pulmonary resection for lung cancer. Am J Surg 192:565–571PubMedCrossRef
31.
Zurück zum Zitat Polley MJ, Seers HE, Cooke HJ, Hoffman C, Paterson C (2007) How to summarise and report written qualitative data from patients: a method for use in cancer support care. Support Care Cancer 15:963–971PubMedCrossRef Polley MJ, Seers HE, Cooke HJ, Hoffman C, Paterson C (2007) How to summarise and report written qualitative data from patients: a method for use in cancer support care. Support Care Cancer 15:963–971PubMedCrossRef
32.
Zurück zum Zitat Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE (2000) Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 18:2505–2514PubMed Richardson MA, Sanders T, Palmer JL, Greisinger A, Singletary SE (2000) Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 18:2505–2514PubMed
33.
Zurück zum Zitat Schag CA, Ganz PA, Wing DS, Sim MS, Lee JJ (1994) Quality of life in adult survivors of lung, colon and prostate cancer. Qual Life Res Int J Qual Life Asp Treat Care Rehab 3:127–141CrossRef Schag CA, Ganz PA, Wing DS, Sim MS, Lee JJ (1994) Quality of life in adult survivors of lung, colon and prostate cancer. Qual Life Res Int J Qual Life Asp Treat Care Rehab 3:127–141CrossRef
34.
Zurück zum Zitat Seers HE, Gale N, Paterson C, Cooke HJ, Tuffrey V, Polley MJ (2009) Individualised and complex experiences of integrative cancer support care: combining qualitative and quantitative data. Support Care Cancer 17:1159–1167PubMedCrossRef Seers HE, Gale N, Paterson C, Cooke HJ, Tuffrey V, Polley MJ (2009) Individualised and complex experiences of integrative cancer support care: combining qualitative and quantitative data. Support Care Cancer 17:1159–1167PubMedCrossRef
35.
Zurück zum Zitat Shumay DM, Maskarinec G, Gotay CC, Heiby EM, Kakai H (2002) Determinants of the degree of complementary and alternative medicine use among patients with cancer. J Altern Complement Med 8:661–671PubMedCrossRef Shumay DM, Maskarinec G, Gotay CC, Heiby EM, Kakai H (2002) Determinants of the degree of complementary and alternative medicine use among patients with cancer. J Altern Complement Med 8:661–671PubMedCrossRef
36.
37.
Zurück zum Zitat Sparreboom A, Cox MC, Acharya MR, Figg WD (2004) Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol 22:2489–2503PubMedCrossRef Sparreboom A, Cox MC, Acharya MR, Figg WD (2004) Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol 22:2489–2503PubMedCrossRef
38.
Zurück zum Zitat Tanaka K, Akechi T, Okuyama T, Nishiwaki Y, Uchitomi Y (2002) Impact of dyspnea, pain, and fatigue on daily life activities in ambulatory patients with advanced lung cancer. J Pain Symptom Manag 23:417–423CrossRef Tanaka K, Akechi T, Okuyama T, Nishiwaki Y, Uchitomi Y (2002) Impact of dyspnea, pain, and fatigue on daily life activities in ambulatory patients with advanced lung cancer. J Pain Symptom Manag 23:417–423CrossRef
39.
Zurück zum Zitat Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, Dahlin CM, Blinderman CD, Jacobsen J, Pirl WF, Billings JA, Lynch TJ (2010) Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 363:733–742PubMedCrossRef Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, Dahlin CM, Blinderman CD, Jacobsen J, Pirl WF, Billings JA, Lynch TJ (2010) Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 363:733–742PubMedCrossRef
40.
Zurück zum Zitat Watson M, Pruyn J, Greer S, van den Borne B (1990) Locus of control and adjustment to cancer. Psychol Rep 66:39–48PubMedCrossRef Watson M, Pruyn J, Greer S, van den Borne B (1990) Locus of control and adjustment to cancer. Psychol Rep 66:39–48PubMedCrossRef
41.
Zurück zum Zitat Wells M, Sarna L, Cooley ME, Brown JK, Chernecky C, Williams RD, Padilla G, Danao LL (2007) Use of complementary and alternative medicine therapies to control symptoms in women living with lung cancer. Cancer Nurs 30:45–55, quiz 56–47PubMedCrossRef Wells M, Sarna L, Cooley ME, Brown JK, Chernecky C, Williams RD, Padilla G, Danao LL (2007) Use of complementary and alternative medicine therapies to control symptoms in women living with lung cancer. Cancer Nurs 30:45–55, quiz 56–47PubMedCrossRef
42.
Zurück zum Zitat Yates JS, Mustian KM, Morrow GR, Gillies LJ, Padmanaban D, Atkins JN, Issell B, Kirshner JJ, Colman LK (2005) Prevalence of complementary and alternative medicine use in cancer patients during treatment. Support Care Cancer 13:806–811PubMedCrossRef Yates JS, Mustian KM, Morrow GR, Gillies LJ, Padmanaban D, Atkins JN, Issell B, Kirshner JJ, Colman LK (2005) Prevalence of complementary and alternative medicine use in cancer patients during treatment. Support Care Cancer 13:806–811PubMedCrossRef
Metadaten
Titel
Does perceived control predict Complementary and Alternative Medicine (CAM) use among patients with lung cancer? A cross-sectional survey
verfasst von
Joshua Bauml
Corey J. Langer
Tracey Evans
Sheila N. Garland
Krupali Desai
Jun J. Mao
Publikationsdatum
01.09.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 9/2014
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-014-2220-5

Weitere Artikel der Ausgabe 9/2014

Supportive Care in Cancer 9/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.